person · Reporting owner

PATIENCE JOHN

Disclosed activity across 3 companies

Tapewire entity: 33236
SEC CIK: 0001021413

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Accelerate Diagnostics, IncAXDX · Entity 78156	Director	December 03, 2024	December 03, 2024
BIODESIX INCBDSX · Entity 6053	Director · Chairman	September 30, 2026	October 03, 2026
STERICYCLE INCSRCL · Entity 80873	Director	May 23, 2018	May 25, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Accelerate Diagnostics, Inc

Report date December 03, 2024 · Filed December 03, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy John Patience Living Trust dated 7/23/1993	653,224	Reported balance After 2024-12-03 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-12-03 · Purchase · Acquired 200,000 · Balance 653,224 F1: Represents shares purchased by the reporting person from Jack Schuler, a member of the issuer's board of directors, in a private transaction. F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.
Common StockSEC Table I · non-derivative	IndirectBy IRA	3,941	Reported balance Holding disclosure · report date 2024-12-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,941
Common StockSEC Table I · non-derivative	IndirectBy Patience Enterprises LP	214,046	Reported balance Holding disclosure · report date 2024-12-03 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 214,046 F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares purchased by the reporting person from Jack Schuler, a member of the issuer's board of directors, in a private transaction.

F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.

F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

BIODESIX INC

Report date September 30, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	26,743	Reported balance After 2026-09-30 transaction · row 1 1 source row Row 1 · 2026-09-30 · Exercise / conversion · Acquired 1,360 · Balance 26,743 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,361	Reported balance After 2026-09-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-30 · Exercise / conversion · Disposed 1,360 · Balance 1,361 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F4: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Common StockSEC Table I · non-derivative	IndirectBy Patience Enterprises LP	107,664	Reported balance Holding disclosure · report date 2026-09-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 107,664 F2: The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy John Patience Living Trust dated 7/23/1993	241,480	Reported balance Holding disclosure · report date 2026-09-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 241,480 F3: The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).
Common StockSEC Table I · non-derivative	IndirectBy Spouse	2,649	Reported balance Holding disclosure · report date 2026-09-30 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 2,649

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

F2: The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F3: The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).

F4: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

STERICYCLE INC

Report date May 23, 2018 · Filed May 25, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	3,878	Reported balance After 2018-05-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-05-23 · Grant · Acquired 1,970 · Balance 3,878 F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 30, 2026 Filed Oct 3, 2026 00:13 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	1,360	$0.00	$0.00	Disclosure SEC source: 0000905148-26-004336 · form4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,361 Underlying: Common Stock · 1,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F4 · derivative.exercise_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
September 30, 2026 Filed Oct 3, 2026 00:13 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	1,360	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-26-004336 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). Read SEC document
June 30, 2026 Filed Jul 2, 2026 20:27 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	1,361	$0.00	$0.00	Disclosure SEC source: 0000905148-26-003146 · form4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,721 Underlying: Common Stock · 1,361 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F4 · derivative.exercise_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
June 30, 2026 Filed Jul 2, 2026 20:27 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	1,361	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-26-003146 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:52 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	1,361	$0.00	$0.00	Disclosure SEC source: 0000905148-26-001495 · form4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,082 Underlying: Common Stock · 1,361 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F4 · derivative.exercise_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:52 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	1,361	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-26-001495 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). Read SEC document
January 05, 2026 Filed Jan 6, 2026 21:26 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	1,143	$0.00	$0.00	Disclosure SEC source: 0000905148-26-000072 · form4.xml · derivative · entry 7 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F6 · derivative.exercise_date: These RSUs vested in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date. F6 · derivative.expiration_date: These RSUs vested in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date. Read SEC document
January 05, 2026 Filed Jan 6, 2026 21:26 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	1,143	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-26-000072 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:26 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	6,354	$0.00 Strike: $6.46	$0.00	Disclosure SEC source: 0000905148-26-000072 · form4.xml · derivative · entry 6 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Underlying: Common Stock · 6,354 shares Expires 2036-01-01 F5 · derivative.exercise_date: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:26 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	5,443	$0.00	$0.00	Disclosure SEC source: 0000905148-26-000072 · form4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,443 Underlying: Common Stock · 5,443 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F4 · derivative.exercise_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
September 30, 2025 Filed Oct 2, 2025 20:04 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	1,144	$0.00	$0.00	Disclosure SEC source: 0000905148-25-003485 · form4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,143 Underlying: Common Stock · 1,144 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5 · derivative.exercise_date: These RSUs vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F1 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document
September 30, 2025 Filed Oct 2, 2025 20:04 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	1,144	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-25-003485 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F2 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document
June 30, 2025 Filed Jul 2, 2025 20:33 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	22,874	$0.00	$0.00	Disclosure SEC source: 0000905148-25-002317 · form4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,747 Underlying: Common Stock · 22,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: These RSUs vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
June 30, 2025 Filed Jul 2, 2025 20:33 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	22,874	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-25-002317 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
May 20, 2025 Filed May 22, 2025 20:16 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	42,010	$0.00 Strike: $0.27	$0.00	Disclosure SEC source: 0000905148-25-001896 · form4.xml · derivative · entry 2 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,010 Underlying: Common Stock · 42,010 shares Expires 2035-05-19 F3 · derivative.exercise_date: This option will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document
May 20, 2025 Filed May 22, 2025 20:16 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	68,621	$0.00	$0.00	Disclosure SEC source: 0000905148-25-001896 · form4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,621 Underlying: Common Stock · 68,621 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document
March 31, 2025 Filed Apr 2, 2025 20:25 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	46,686	$0.00	$0.00	Disclosure SEC source: 0000905148-25-001047 · form4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: These RSUs vested in full on March 31, 2025, and had no expiration date. F4 · derivative.expiration_date: These RSUs vested in full on March 31, 2025, and had no expiration date. Read SEC document
March 31, 2025 Filed Apr 2, 2025 20:25 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	46,686	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-25-001047 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
December 03, 2024 Filed Dec 3, 2024 20:48 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock	200,000	$1.57	$314,000.00	Disclosure SEC source: 0001104659-24-125217 · tm2430099-2_4seq1.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 653,224 F1 · shares: Represents shares purchased by the reporting person from Jack Schuler, a member of the issuer's board of directors, in a private transaction. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust. Read SEC document
November 05, 2024 Filed Nov 6, 2024 20:16 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	75,000	$1.38	$103,710.00	Disclosure SEC source: 0000905148-24-002948 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 2,153,298 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3461 to $1.4186, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 23, 2024 Filed May 23, 2024 23:12 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionSeries A Non-Voting Convertible Preferred Stock · Derivative	5,435	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001605 · form4.xml · derivative · entry 7 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 0 Underlying: Common Stock · 217,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.exercise_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.expiration_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F2 · ownership.nature: The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993). Read SEC document
May 23, 2024 Filed May 23, 2024 23:12 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	217,400	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-24-001605 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 4,829,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F2 · ownership.nature: The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993). Read SEC document
May 21, 2024 Filed May 23, 2024 23:12 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	37,050	$0.00 Strike: $1.57	$0.00	Disclosure SEC source: 0000905148-24-001605 · form4.xml · derivative · entry 6 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,050 Underlying: Common Stock · 37,050 shares Expires 2034-05-20 F6 · derivative.exercise_date: This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
May 21, 2024 Filed May 23, 2024 23:12 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	46,686	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001605 · form4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,686 Underlying: Common Stock · 46,686 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Common Stock. F5 · derivative.exercise_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F5 · derivative.expiration_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
May 20, 2024 Filed May 21, 2024 19:02 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantRestricted Stock Units · Derivative	66,667	$0.00	$0.00	Disclosure SEC source: 0001104659-24-063965 · tm2415084-4_4seq1.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F2 · derivative.exercise_date: On May 20, 2024, the reporting person was granted a total of 66,667 RSUs, which vest on the first-year anniversary of the grant date, unless the reporting person leaves in good standing before such vesting date, in which case the RSUs will vest pro-rata based on months served. F2 · derivative.expiration_date: On May 20, 2024, the reporting person was granted a total of 66,667 RSUs, which vest on the first-year anniversary of the grant date, unless the reporting person leaves in good standing before such vesting date, in which case the RSUs will vest pro-rata based on months served. Read SEC document
April 05, 2024 Filed Apr 9, 2024 23:33 UTC	BIODESIX INC BDSX · Entity 6053	GrantSeries A Non-Voting Convertible Preferred Stock · Derivative	5,435	$46.00	$250,010.00	Disclosure SEC source: 0000905148-24-001140 · form4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 5,435 Underlying: Common Stock · 217,400 shares Expires not disclosed F1 · derivative.exercise_price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.exercise_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F2 · ownership.nature: The Reporting Person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:10 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock Warrants (right to buy) · Derivative	16,666	Not disclosed Strike: $1.65	Not disclosed	Disclosure SEC source: 0001104659-24-006670 · tm244005-5_4seq1.xml · derivative · entry 4 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2029-01-23 F1 · price: The reported securities are included within 16,666 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:10 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock	16,666	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-006670 · tm244005-5_4seq1.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 453,224 F1 · price: The reported securities are included within 16,666 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. Read SEC document
January 01, 2024 Filed Jan 3, 2024 21:14 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	105,389	$0.00	$0.00	Disclosure SEC source: 0000905148-24-000038 · form4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,262 Underlying: Common Stock · 105,389 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:32 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	61,728	$1.62	$99,999.36	Disclosure SEC source: 0000905148-23-000626 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 4,612,211 F1 · ownership.direct: The Reporting Person is the sole trustee of John Patience Trust (July 23, 1993). F1 · ownership.nature: The Reporting Person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document
June 28, 2023 Filed Jun 29, 2023 17:59 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantEmployee Restricted Stock Units · Derivative	236,842	$0.00	$0.00	Disclosure SEC source: 0001628280-23-023938 · wk-form4_1688075963.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,842 Underlying: Common Stock · 236,842 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: On June 28, 2023, the reporting person was granted RSUs which vest in equal amounts each year for 5 years, with the first installment vesting on June 28, 2024. F3 · derivative.expiration_date: Not applicable. Read SEC document
May 29, 2023 Filed Jun 1, 2023 18:27 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantEmployee Restricted Stock Units · Derivative	78,947	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020566 · wk-form4_1685658466.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,947 Underlying: Common Stock · 78,947 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: On May 29, 2023, the reporting person was granted RSUs. All of the RSUs shall vest on the first-year anniversary of the Date of Grant (the "Vesting Date"), unless Grantee leaves in good standing before 12 months, in which case they will vest pro-rata based on months served. Pursuant to the issuer's Director Equity Deferral Program, the reporting person has elected to defer receipt of the shares of common stock upon vesting of the restricted stock units to such time that is within 30 days following his departure from the issuer's board of directors. F3 · derivative.expiration_date: Not applicable. Read SEC document
May 23, 2023 Filed May 25, 2023 22:22 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	28,873	$0.00	$0.00	Disclosure SEC source: 0001140361-23-026720 · form4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,873 Underlying: Common Stock · 28,873 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F4 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. F4 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:31 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	4,878	$0.00	$0.00	Disclosure SEC source: 0001140361-23-000672 · form4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,711 Underlying: Common Stock · 4,878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document
January 01, 2023 Filed Jan 4, 2023 23:21 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	62,500	$0.00	$0.00	Disclosure SEC source: 0001140361-23-000520 · form4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,833 Underlying: Common Stock · 62,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document
November 21, 2022 Filed Nov 21, 2022 23:03 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	1,739,130	$1.15	$1,999,999.50	Disclosure SEC source: 0001140361-22-042602 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 4,550,483 F1 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F1 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document
May 31, 2022 Filed Jun 2, 2022 16:21 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantEmployee Restricted Stock Units · Derivative	75,949	$0.00	$0.00	Disclosure SEC source: 0001628280-22-016061 · wf-form4_165420127815825.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,949 Underlying: Common Stock · 75,949 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on May 31, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Pursuant to the issuer's Director Equity Deferral Program, the reporting person has elected to defer receipt of the shares of common stock upon vesting of the restricted stock units to such time that is within 30 days following his departure from the issuer's board of directors. F3 · derivative.expiration_date: Not applicable. Read SEC document
May 24, 2022 Filed May 26, 2022 20:15 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	83,333	$0.00	$0.00	Disclosure SEC source: 0001140361-22-020782 · form4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and has no expiration date. F3 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. Read SEC document
April 07, 2022 Filed Apr 11, 2022 20:39 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	279,329	$1.79	$499,998.91	Disclosure SEC source: 0001567619-22-008354 · doc1.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,926 Read SEC document
December 30, 2021 Filed Jan 4, 2022 21:59 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	22,988	$4.35	$99,997.80	Disclosure SEC source: 0001567619-22-000275 · doc1.xml · nonDerivative · entry 2 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 52,988 Read SEC document
December 30, 2021 Filed Jan 4, 2022 21:59 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	137,931	$4.35	$599,999.85	Disclosure SEC source: 0001567619-22-000275 · doc1.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 2,078,298 F1 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
November 23, 2021 Filed Nov 24, 2021 19:57 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	10,000	$6.18	$61,753.00	Disclosure SEC source: 0001567619-21-021148 · doc1.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 1,940,367 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.74 to $6.38, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F1 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
November 18, 2021 Filed Nov 22, 2021 20:33 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	9,497	$6.34	$60,219.53	Disclosure SEC source: 0001567619-21-020954 · doc1.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 1,930,367 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.14 to $6.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F1 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
September 30, 2021 Filed Dec 10, 2021 15:57 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantCommon Stock	21,702	$7.68	$166,671.36	Disclosure SEC source: 0001628280-21-024838 · wf-form4_163916981210596.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 4,365,585 F1 · shares: Represents shares purchased by the reporting person from Accelerate Diagnostics, Inc. in connection with the closing of the third and final tranche of an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The third and final tranche of the offering closed on September 30, 2021. Read SEC document
August 19, 2021 Filed Aug 23, 2021 19:01 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	8,396	$8.04	$67,489.57	Disclosure SEC source: 0001567619-21-016211 · doc1.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 1,920,870 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.80 to $8.325, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F1 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
August 17, 2021 Filed Aug 19, 2021 19:00 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	1,604	$7.12	$11,416.31	Disclosure SEC source: 0000905148-21-000612 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 1,912,474 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.94 to $7.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F4 · balance_after: In the Form 4 filed by the Reporting Person on November 3, 2020, and each subsequent Form 4, the Amount of Securities Beneficially Owned in Table I was inadvertently overstated by 98 shares. This Form 4 corrects, in Table I, the Amount of Securities Beneficially Owned by the Reporting Person. F1 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
June 29, 2021 Filed Jul 1, 2021 22:21 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to buy) · Derivative	34,385	$0.00 Strike: $13.72	$0.00	Disclosure SEC source: 0000905148-21-000536 · form4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,385 Underlying: Common Stock · 34,385 shares Expires 2031-06-28 F1 · derivative.exercise_date: This option will vest in full on March 31, 2022. Read SEC document
May 20, 2021 Filed May 24, 2021 21:59 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantStock Option (right to buy) · Derivative	35,168	$0.00 Strike: $7.68	$0.00	Disclosure SEC source: 0001104659-21-071495 · tm2117458d4_form4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,168 Underlying: Common Stock · 35,168 shares Expires 2031-05-20 F1 · derivative.exercise_date: The option vests in full on May 20, 2022. Read SEC document
April 09, 2021 Filed Apr 13, 2021 16:20 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantCommon Stock	21,701	$7.68	$166,663.68	Disclosure SEC source: 0001628280-21-006838 · wf-form4_161834521821855.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 4,343,883 F1 · shares: Represents shares purchased by the reporting person from Accelerate Diagnostics, Inc. in connection with the closing of the second tranche of an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The second tranche of the offering closed on April 9, 2021. Read SEC document
February 19, 2021 Filed Feb 23, 2021 19:57 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantCommon Stock	21,701	$7.68	$166,663.68	Disclosure SEC source: 0001104659-21-026983 · tm217603d3_4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 4,322,182 F1 · shares: Represents shares purchased by the reporting person from Accelerate Diagnostics, Inc. in connection with the closing of the first tranche of an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The first tranche of the offering closed on February 19, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.